Perimeter Medical Imaging AI (OTCPK:PYNK.F) 2025 Conference Transcript

Summary of Perimeter Medical Imaging AI Conference Call Company Overview - Company: Perimeter Medical Imaging AI - Ticker Symbols: OTCQX: PYNKF, TSXV: PINK - Industry: Medical Imaging Technology, specifically focused on cancer surgery Core Issues Addressed - Problem Statement: High rates of reoperations in cancer surgeries due to incomplete removal of cancerous tissues, leading to emotional and financial burdens on patients, hospitals, and insurers [4][10][12] - Statistics: - Breast cancer reoperation rate: 23% - Thyroid cancer reoperation rate: 12% - Prostate cancer reoperation rate: 21% [6][7] Technology and Solutions - Imaging Technology: Optical Coherence Tomography (OCT) provides high-resolution imaging (10x better than X-ray, 100x better than MRI) to visualize cancerous cells in real-time during surgery [13][14] - Device Description: The imaging system allows surgeons to see cellular-level details and make informed decisions during surgery, potentially reducing reoperation rates [16][22] - AI Integration: Future products will incorporate AI algorithms to assist surgeons by highlighting suspicious areas in real-time, thus improving efficiency and accuracy [20][26][28] Market Opportunity - Total Addressable Market (TAM): Estimated at $17 billion globally, with a U.S. market of $4 billion and a specific breast cancer surgery market of $650 million [36][37] - Annual Healthcare Costs: Over $1 billion in healthcare costs due to re-excisions, not including emotional costs and survival rates [32][33] Clinical Results and Performance - Clinical Trials: Successful trials with major cancer institutions, showing significant improvements in reoperation rates [31][40] - Surgeon Feedback: Surgeons using the technology reported reoperation rates dropping from 20% to around 5% [39][41] Financial Performance - Revenue Growth: Revenue increased from a few hundred thousand to over half a million per quarter, primarily driven by high-margin recurring revenue from consumables [43][44] - Gross Margin: Approximately 90% gross margin on consumables, indicating a strong business model [44] Competitive Advantages - Intellectual Property: Strong patent protection around imaging technology and proprietary algorithms, making it difficult for competitors to replicate [47] - Market Demand: Surgeons are driving demand for the technology, leading to increased adoption and market share [38][42] Future Outlook - Regulatory Approval: The AI-enabled device is undergoing FDA approval, expected to be on the market by Q2 of the following year [55][56] - Growth Strategy: Focus on expanding market presence and increasing the number of devices in use to drive consumable sales [57] Leadership Team - Key Members: - Adrian Mendes, CEO - Sarah O'Brien, CFO - Dr. Ted James, Chief Medical Officer [49][50] Conclusion - Perimeter Medical Imaging AI is positioned to significantly impact cancer surgery outcomes through innovative imaging technology and AI integration, with a strong market opportunity and a solid growth trajectory ahead [51][58]